Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alivus Life Sciences's Total Assets for the quarter that ended in Jun. 2026 was ₹0 Mil.
Warning Sign:
If a company builds assets at 11.7% a year, faster than its revenue growth rate of 5.6% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Alivus Life Sciences's average Total Assets Growth Rate was 10.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 9.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.70% per year.
During the past 8 years, Alivus Life Sciences's highest 3-Year average Total Assets Growth Rate was 13.60%. The lowest was 9.40%. And the median was 11.10%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Alivus Life Sciences's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Alivus Life Sciences Total Assets Related Terms
Alivus Life Sciences Total Assets Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Alivus Life Sciences's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (BOM:543322) has a Total Assets of ₹0 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' Total Assets too high?
Alivus Life Sciences' current Total Assets is ₹0 Mil. Overall, Alivus Life Sciences has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Total Assets compare to ZTS?
Alivus Life Sciences' Total Assets of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Alivus Life Sciences and its competitors. Alivus Life Sciences's current Total Assets is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (BOM:543322) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,023.99, compared to a current price of ₹1,157.00 — trading 13% above its estimated fair value. The current Total Assets is ₹0 Mil. Alivus Life Sciences' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Alivus Life Sciences (BOM:543322), the current Total Assets is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (BOM:543322) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,157.00 is trading 13% above its estimated GF Value™ of ₹1,023.99.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for BOM:543322:
Total Assets: ₹0 Mil
GF Value™: ₹1,023.99 vs. price of ₹1,157.00 (13% above fair value)
No single metric tells the full story. See the BOM:543322 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
84GF Score
Get the complete analysis for BOM:543322
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543322 has been successfully added to your 
